Daily Stock Analysis, ACHN, Achillion Pharmaceuticals Inc, priceseries

Achillion Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
3.55
Close
3.43
High
3.55
Low
3.38
Previous Close
3.56
Daily Price Gain
-0.13
YTD High
5.66
YTD High Date
Aug 9, 2017
YTD Low
2.95
YTD Low Date
Nov 15, 2017
YTD Price Change
-0.68
YTD Gain
-16.55%
52 Week High
5.66
52 Week High Date
Aug 9, 2017
52 Week Low
2.95
52 Week Low Date
Nov 15, 2017
52 Week Price Change
-1.04
52 Week Gain
-23.27%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 18. 2015
9.81
Jan 5. 2016
10.31
10 Trading Days
5.10%
Link
LONG
Apr 12. 2016
8.12
Apr 29. 2016
8.59
13 Trading Days
5.78%
Link
LONG
May 20. 2016
8.42
Jun 13. 2016
9.31
15 Trading Days
10.59%
Link
LONG
May 24. 2017
4.14
Jun 7. 2017
4.53
9 Trading Days
9.36%
Link
LONG
Sep 27. 2017
4.37
Oct 11. 2017
4.59
10 Trading Days
5.03%
Link
Company Information
Stock Symbol
ACHN
Exchange
NasdaqGS
Company URL
http://www.achillion.com
Company Phone
203-624-7000
CEO
Milind S. Deshpande
Headquarters
Connecticut
Business Address
300 GEORGE STREET, NEW HAVEN, CT 06511
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001070336
About

Achillion Pharmaceuticals, Inc. engages in the research and development of small molecule drug therapies for infectious diseases and immune system disorders. It intends to commercialize its anti-viral medicines for the treatment of hepatitis C and resistant bacterial infections. The company was founded on August 17, 1998 and is headquartered in New Haven, CT.

Description

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. Its drug candidates for treating chronic hepatitis C virus (HCV) infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. The company is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors. It has a license and development agreement with Ora, Inc. for the development and commercialization of ACH-702, a drug candidate that is delivered topically or locally; and collaboration arrangement with Janssen Pharmaceuticals Inc. to develop and commercialize antiviral drug candidates for treating HCV infection. The company was founded in 1998 and is headquartered in New Haven, Connecticut.